HRP20100700T1 - Vr1 benzimidazol modulatori - Google Patents

Vr1 benzimidazol modulatori Download PDF

Info

Publication number
HRP20100700T1
HRP20100700T1 HR20100700T HRP20100700T HRP20100700T1 HR P20100700 T1 HRP20100700 T1 HR P20100700T1 HR 20100700 T HR20100700 T HR 20100700T HR P20100700 T HRP20100700 T HR P20100700T HR P20100700 T1 HRP20100700 T1 HR P20100700T1
Authority
HR
Croatia
Prior art keywords
phenyl
benzimidazol
vinyl
trifluoromethyl
benzenesulfonamide
Prior art date
Application number
HR20100700T
Other languages
English (en)
Croatian (hr)
Inventor
L. Calvo Raul
R. Player Mark
L. Dax Scott
H. Parsons William
Brandt Michael
Patel Sharmila
Liu Jian
S. Cheung Wing
C. Jetter Michele
Lee Yu-Kai
A. Youngman Mark
Pan Wenxi
M. Wells Keneth
A. Beauchamp Derek
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20100700T1 publication Critical patent/HRP20100700T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
HR20100700T 2006-05-03 2010-12-17 Vr1 benzimidazol modulatori HRP20100700T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79750406P 2006-05-03 2006-05-03
PCT/US2007/066748 WO2007130780A2 (en) 2006-05-03 2007-04-17 Benzimidazole modulators of vr1

Publications (1)

Publication Number Publication Date
HRP20100700T1 true HRP20100700T1 (hr) 2011-02-28

Family

ID=38566108

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100700T HRP20100700T1 (hr) 2006-05-03 2010-12-17 Vr1 benzimidazol modulatori

Country Status (37)

Country Link
US (3) US7951829B2 (ar)
EP (1) EP2021330B1 (ar)
JP (1) JP5302884B2 (ar)
KR (1) KR101434883B1 (ar)
CN (1) CN101511797B (ar)
AR (1) AR060840A1 (ar)
AT (1) ATE482201T1 (ar)
AU (1) AU2007248341C1 (ar)
BR (1) BRPI0709803B8 (ar)
CA (1) CA2651128C (ar)
CO (1) CO6160329A2 (ar)
CR (1) CR10479A (ar)
CY (1) CY1111269T1 (ar)
DE (1) DE602007009378D1 (ar)
DK (1) DK2021330T3 (ar)
EA (1) EA019386B1 (ar)
EC (1) ECSP088854A (ar)
ES (1) ES2350959T3 (ar)
HK (1) HK1131971A1 (ar)
HR (1) HRP20100700T1 (ar)
IL (1) IL194916A (ar)
JO (1) JO3602B1 (ar)
MX (1) MX2008014108A (ar)
MY (1) MY154595A (ar)
NI (1) NI200800290A (ar)
NO (1) NO341965B1 (ar)
NZ (1) NZ572251A (ar)
PE (1) PE20080065A1 (ar)
PL (1) PL2021330T3 (ar)
PT (1) PT2021330E (ar)
RS (1) RS51473B (ar)
SI (1) SI2021330T1 (ar)
TW (1) TWI419882B (ar)
UA (1) UA94749C2 (ar)
UY (1) UY30322A1 (ar)
WO (1) WO2007130780A2 (ar)
ZA (1) ZA200810234B (ar)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007333990A1 (en) 2006-12-15 2008-06-26 Janssen Pharmaceutica N.V. Benzimidazole TRPV1 inhibitors
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
PE20091102A1 (es) 2007-12-17 2009-07-25 Janssen Pharmaceutica Nv Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
US20090156598A1 (en) * 2007-12-17 2009-06-18 Lebsack Alec D Imidazolopyrimidine modulators of TRPV1
US8362012B2 (en) * 2008-04-18 2013-01-29 Daewoong Pharmaceutical Co., Ltd. Benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof
US8232409B2 (en) 2008-10-15 2012-07-31 Janssen Pharmaceutica N.V. Heterocyclic benzimidazoles as TRPM8 modulators
US8217060B2 (en) * 2009-05-15 2012-07-10 Janssen Pharmaceutica, Nv Benzimidazole derivatives useful as TRP M8 receptor modulators
US8323805B2 (en) * 2009-06-04 2012-12-04 Nitto Denko Corporation Emissive aryl-heteroaryl acetylenes
CN102002010A (zh) * 2009-08-31 2011-04-06 住友化学株式会社 双噁唑啉基烷烃化合物的精制方法
US8802683B2 (en) * 2011-05-16 2014-08-12 Cellceutix Corporation Compounds for use in treatment of mucositis
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
CN105229003B (zh) 2013-03-14 2017-03-15 诺华股份有限公司 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物
ES2707961T3 (es) 2013-07-11 2019-04-08 Bristol Myers Squibb Co Inhibidores de IDO
WO2015066241A1 (en) 2013-10-30 2015-05-07 Novartis Ag 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
CN108026071A (zh) * 2015-09-08 2018-05-11 住友化学株式会社 制备三唑化合物的方法
EP3534888B1 (en) * 2016-11-01 2022-04-06 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
BR112020021967A2 (pt) * 2018-05-03 2021-01-26 Jiangsu Hengrui Medicine Co., Ltd. derivados de benzimidazol como moduladores de receptor gama órfão relacionado a retinoides (ror¿) e usos farmacêuticos dos mesmos
CN108997398B (zh) * 2018-07-23 2020-12-15 被忽略疾病药物研发组织 一种3,3-二甲基苯并[c][1,2]氧杂戊硼烷-1(3h)-醇的制备方法
CN112745268B (zh) * 2019-10-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并咪唑衍生物的晶型及制备方法
US20220411380A1 (en) * 2019-10-31 2022-12-29 Jiangsu Hengrui Medicine Co., Ltd. ACID ADDITION SALT OF RORy REGULATOR
WO2021248008A1 (en) 2020-06-05 2021-12-09 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US6299796B1 (en) 1997-12-18 2001-10-09 Fuji Photo Film Co., Ltd. Styryl compound, method for the preparation thereof and electroluminescent element employing the same
US6748803B1 (en) * 2000-02-22 2004-06-15 Simmonds Precison Products, Inc. Liquid measurement system and shared interface apparatus for use therein
US7582761B2 (en) * 2002-10-17 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
TW200418806A (en) 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
DE602004015620D1 (de) * 2003-07-28 2008-09-18 Janssen Pharmaceutica Nv Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren
JP2007521325A (ja) * 2003-10-28 2007-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なベンズイミダゾール
WO2006058338A2 (en) * 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor
CA2654246A1 (en) * 2006-07-04 2008-01-10 Janssen Pharmaceutica N.V. Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group
AU2007333990A1 (en) * 2006-12-15 2008-06-26 Janssen Pharmaceutica N.V. Benzimidazole TRPV1 inhibitors

Also Published As

Publication number Publication date
CA2651128C (en) 2014-09-02
KR20090008428A (ko) 2009-01-21
CO6160329A2 (es) 2010-05-20
IL194916A (en) 2013-01-31
ECSP088854A (es) 2008-11-27
EA200870497A1 (ru) 2009-06-30
US20110190344A1 (en) 2011-08-04
ATE482201T1 (de) 2010-10-15
DE602007009378D1 (de) 2010-11-04
EA019386B1 (ru) 2014-03-31
WO2007130780A3 (en) 2008-02-14
US20070259936A1 (en) 2007-11-08
CN101511797B (zh) 2013-01-02
PL2021330T3 (pl) 2011-03-31
TWI419882B (zh) 2013-12-21
AU2007248341B2 (en) 2011-12-08
ZA200810234B (en) 2010-02-24
EP2021330B1 (en) 2010-09-22
CA2651128A1 (en) 2007-11-15
PT2021330E (pt) 2010-12-03
WO2007130780A2 (en) 2007-11-15
MX2008014108A (es) 2008-11-14
KR101434883B1 (ko) 2014-08-27
MY154595A (en) 2015-06-30
US20110190364A1 (en) 2011-08-04
CR10479A (es) 2009-03-31
DK2021330T3 (da) 2010-12-06
TW200808738A (en) 2008-02-16
IL194916A0 (en) 2009-08-03
JP2009535414A (ja) 2009-10-01
JP5302884B2 (ja) 2013-10-02
UY30322A1 (es) 2007-08-31
CY1111269T1 (el) 2015-08-05
NO341965B1 (no) 2018-03-05
AU2007248341A1 (en) 2007-11-15
RS51473B (en) 2011-04-30
BRPI0709803B8 (pt) 2021-05-25
NI200800290A (es) 2012-01-30
ES2350959T3 (es) 2011-01-28
EP2021330A2 (en) 2009-02-11
NZ572251A (en) 2010-08-27
CN101511797A (zh) 2009-08-19
HK1131971A1 (en) 2010-02-12
NO20085031L (no) 2009-01-06
PE20080065A1 (es) 2008-02-25
AU2007248341C1 (en) 2013-01-17
AR060840A1 (es) 2008-07-16
BRPI0709803B1 (pt) 2019-12-10
US7951829B2 (en) 2011-05-31
SI2021330T1 (sl) 2011-01-31
UA94749C2 (en) 2011-06-10
BRPI0709803A2 (pt) 2011-07-26
JO3602B1 (ar) 2020-07-05

Similar Documents

Publication Publication Date Title
HRP20100700T1 (hr) Vr1 benzimidazol modulatori
EP1773330B1 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
JP5749802B2 (ja) 非定型抗精神病薬及びtaar1アゴニストを含む組合せ
ZA200304482B (en) Pyrimidineamines as angiogenesis modulators
JP2008513464A5 (ar)
Ognyanov et al. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure− activity relationships of 2-piperazin-1-yl-1 H-benzimidazoles
HRP20100611T1 (hr) Novi spojevi
Bucolo et al. Controversies in glaucoma: current medical treatment and drug development
JP2011042668A5 (ar)
RU2006102510A (ru) Бензимидазольные, бензтиазольные и бензоксазольные производные и их применение в качестве модуляторов lta4h
FI3743406T3 (fi) Tmem16a-modulaattoreita
TW200811112A (en) Benzimidazole derivatives
RU2010110640A (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
WO2010037081A1 (en) Melanocortin receptor-specific spiro-piperidine compounds
JP2007505083A5 (ar)
JP2007533732A (ja) 線維症を処置するためのc−kit阻害剤の使用法
US20060004075A1 (en) Substituted aryl amides as IP antagonists
KR20120092655A (ko) Cns 장애 치료용 옥사졸린 유도체
CN102209713A (zh) 作为5-羟色胺-6配体的1-(芳磺酰基)-4-(哌嗪-1-基)-1h-苯并咪唑
US20040116443A1 (en) Dopamine D4 ligands for the treatment of novelty-seeking disorders
Quaglia et al. α2C-adrenoceptor modulators: a patent review
US20180042922A1 (en) Compositions and methods of treating a neurodegenerative disease
KR101477872B1 (ko) 신규한 벤즈이미다졸 유도체 및 fxr 작용제로서의 그의 용도
KR20150131647A (ko) 전압개폐 칼슘이온채널 억제 활성화능을 갖는 n-(피라졸릴메틸)아릴설폰아마이드 화합물 및 이를 포함하는 약학적 조성물
JP2004530650A5 (ar)